The growing demand for Venlafaxine Hydrochloride has provided a major boost to the Global Venlafaxine Hydrochloride Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high CAGR and reach values of high millions by the end of the forecast period of 2020 up to 2025.

Global Venlafaxine Hydrochloride Market overview:

Venlafaxine is used to treat major depressive disorder, anxiety, and panic disorder. Venlafaxine is an antidepressant belonging to a group of drugs called selective. Venlafaxine Hydrochloride (AHFS Monograph). Venlafaxine oral tablet is used to treat depression (immediate-release tablet and extended-release tablet). It’s also used to treat social anxiety disorder (extended-release tablet only). The Global Venlafaxine Hydrochloride Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/238522 .

On the Basis of Product Type segment, the Venlafaxine Hydrochloride Market is sub segmented into greater than 98% and less than 98%. Based on End Use Industry segment, the Venlafaxine Hydrochloride Market is segmented as Tablet and Capsule.

There are several manufacturers of Venlafaxine Hydrochloride in Europe and North America. In North America, the demand for Venlafaxine Hydrochloride is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Venlafaxine Hydrochloride Market Report 2020” @ https://www.businessindustryreports.com/buy-now/238522/single .

Top Industry News:

PFIZER AND BIONTECH ANNOUNCE DATA FROM PRECLINICAL STUDIES OF MRNA-BASED VACCINE CANDIDATE AGAINST COVID-19 ON 09 SEPTEMBER, 2020 --  Pfizer Inc. and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. In a non-human primate preclinical study, immunization with the BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection.

“Collectively, these preclinical results, combined with our clinical data collected to date, continue to support the promise and validity of our mRNA-based vaccine program against SARS-CoV-2 and selection of the BNT162b2 candidate, which we believe has the potential to prevent many millions of COVID-19 cases,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We are encouraged by the data thus far and confident in our progress towards developing a safe and effective vaccine candidate to help address this current pandemic.”

“The data we have shared today include the characterization of our lead candidate BNT162b2, as well as key animal studies that were the basis for our clinical programs. They have enabled us to advance BNT162b2 into Phase 3 evaluation,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “This is another development milestone for providing a safe and effective potential vaccine to the global community to help end this pandemic.”

In the preclinical study, BNT162b2 demonstrated protective anti-viral effects in rhesus macaques, with concomitant high neutralizing antibody titers and a TH1-biased cellular response in rhesus macaques and mice. In a viral infection model, macaques that received two injections with 100 µg BNT162b2 and macaques that received saline control injections were challenged 55 days after the second immunization with a very high viral inoculum of approximately 1 million plaque forming units of SARS-CoV-2, via both intranasal (nose) and intratracheal (lung) routes. Immunization with BNT162b2 reduced viral infection with no viral RNA detected in the lower respiratory tract of the immunized animals, while in most non-immunized (saline) animals, there was evidence of viral RNA.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/238522 .

Major Key Players:

Some of the Venlafaxine Hydrochloride Market manufacturers involved in the market are Pfizer, Mesha Pharma, Sun Pharmaceutical Industries, Taj API, Synergy Pharmaceutical, Winsunny Harmony Science & Technology, Suzhou No.4 Pharmaceutical Factory in World, effective mergers are some of the strategies adopted by the Venlafaxine Hydrochloride Market manufacturers. New product launches and continuous technological innovations are the Venlafaxine Hydrochloride Market strategies adopted by the major players.

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

[email protected]

+19376349940